Jazz Pharmaceuticals JAZZ Payments to Acquire Investments
Payments to Acquire Investments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInvestments.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's payments to acquire investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's payments to acquire investments?
- Jazz Pharmaceuticals (JAZZ) reported payments to acquire investments of $500M in Q1 2026.
- How has Jazz Pharmaceuticals's payments to acquire investments changed year-over-year?
- Jazz Pharmaceuticals's payments to acquire investments increased by 13.6% year-over-year, from $440.1M to $500M.
- What is the long-term trend for Jazz Pharmaceuticals's payments to acquire investments?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's payments to acquire investments has grown at a 187.4% compound annual growth rate (CAGR), from $26.82M to $1.83B.
- What does payments to acquire investments mean?
- Cash spent on purchasing financial investments.
- How do you interpret payments to acquire investments?
- Higher outflows indicate active capital deployment into financial assets, while lower outflows suggest a focus on cash preservation or internal reinvestment.
- How does payments to acquire investments compare across companies?
- Commonly reported by firms with significant treasury management or corporate venture arms.